Zacks: Brokerages Anticipate Kura Oncology, Inc. (NASDAQ:KURA) to Post -$0.54 EPS

Equities analysts forecast that Kura Oncology, Inc. (NASDAQ:KURA) will post earnings of ($0.54) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Kura Oncology’s earnings, with the highest EPS estimate coming in at ($0.51) and the lowest estimate coming in at ($0.62). Kura Oncology posted earnings per share of ($0.45) during the same quarter last year, which indicates a negative year over year growth rate of 20%. The firm is expected to announce its next earnings results on Wednesday, February 23rd.

On average, analysts expect that Kura Oncology will report full-year earnings of ($2.01) per share for the current year, with EPS estimates ranging from ($2.10) to ($1.98). For the next financial year, analysts anticipate that the firm will post earnings of ($2.27) per share, with EPS estimates ranging from ($2.85) to ($1.99). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Kura Oncology.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, November 4th. The company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.04. During the same period in the prior year, the business earned ($0.42) earnings per share.

Several research firms have commented on KURA. SVB Leerink boosted their target price on Kura Oncology from $40.00 to $41.00 and gave the stock an “outperform” rating in a report on Friday, August 6th. HC Wainwright dropped their target price on Kura Oncology from $43.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday. Zacks Investment Research raised Kura Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, October 12th. Wedbush reissued an “outperform” rating on shares of Kura Oncology in a report on Monday, November 8th. Finally, Credit Suisse Group dropped their target price on Kura Oncology from $42.00 to $40.00 and set an “outperform” rating on the stock in a report on Friday, August 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $42.71.

A number of hedge funds have recently modified their holdings of the business. Marshall Wace LLP purchased a new stake in shares of Kura Oncology in the first quarter worth approximately $372,000. Dimensional Fund Advisors LP raised its holdings in shares of Kura Oncology by 26.3% in the first quarter. Dimensional Fund Advisors LP now owns 819,092 shares of the company’s stock worth $23,104,000 after buying an additional 170,582 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Kura Oncology by 33.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,746 shares of the company’s stock worth $897,000 after buying an additional 7,924 shares during the period. Royal Bank of Canada raised its holdings in shares of Kura Oncology by 1,349.6% in the first quarter. Royal Bank of Canada now owns 9,843 shares of the company’s stock worth $278,000 after buying an additional 9,164 shares during the period. Finally, Schonfeld Strategic Advisors LLC raised its holdings in shares of Kura Oncology by 318.5% in the first quarter. Schonfeld Strategic Advisors LLC now owns 84,702 shares of the company’s stock worth $2,395,000 after buying an additional 64,464 shares during the period.

Shares of NASDAQ KURA traded down $2.58 during mid-day trading on Thursday, hitting $14.02. 6,681,951 shares of the stock traded hands, compared to its average volume of 677,911. Kura Oncology has a 52 week low of $12.32 and a 52 week high of $43.00. The company has a market cap of $933.12 million, a price-to-earnings ratio of -7.30 and a beta of 1.58. The stock has a fifty day moving average price of $18.24 and a 200-day moving average price of $19.58.

About Kura Oncology

Kura Oncology, Inc operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias.

Featured Story: Asset Allocation and Your Retirement

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.